

NCT ID	NCT06010901
Title	A Clinical Study of TQB2618 Injection Monotherapy and Combination Regimen (With Penpulimab Injection ±Anlotinib Hydrochloride Capsules) in the Four or Later Lines of Treatment of Advanced Colorectal Cancer.
Phase	Phase 1
Date Added	2023-08-25
Location	China
Prior IO Allowed	Yes
CRC-directed	Yes
Status	Recruiting
Drugs	Anlotinib hydrochloride capsules, Penpulimab Injection, TQB2618 injection
Tags	MSI-H/ MMRd, MSS/ MMRp
NCT ID	NCT06011772
Title	A Phase 0 Study of EGF-Depleting Therapy CIMAvax-EGF in Combination With Standard Therapy for RAS- and BRAF Wild-Type Metastatic Colorectal Cancer
Phase	Early Phase 1
Date Added	2023-08-25
Location	New York, United States
Prior IO Allowed	Yes
CRC-directed	Yes
Status	Active, not recruiting
Drugs	fluorouracil, Irinotecan, Leucovorin, oxaliplatin
Tags	MSI-H/ MMRd, MSS/ MMRp
NCT ID	NCT06013111
Title	An Exploratory Clinical Study Evaluating the Safety and Efficacy of Anti-CEA-CAR-T Cells Injection in Patients With CEA+ Locally Advanced and/or Metastatic Solid Tumors
Phase	Phase 1
Date Added	2023-08-28
Location	China
Prior IO Allowed	Yes
CRC-directed	Yes
Status	Recruiting
Drugs	
Tags	MSI-H/ MMRd, MSS/ MMRp
NCT ID	NCT06099821
Title	KN046 Plus Regorafenib or Apatinib in MSI-H Digestive System Cancers Resistant to PD-1/PD-L1 Blockade
Phase	Phase 2
Date Added	2023-10-25
Location	China
Prior IO Allowed	Yes
CRC-directed	Yes
Status	Recruiting
Drugs	apatinib, KN046, Regorafenib
Tags	MSI-H/ MMRd
NCT ID	NCT06102902
Title	Testing the Addition of Anti-cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment, Cetuximab Plus Encorafenib, for Refractory BRAF V600E mCRC
Phase	Phase 1

Date Added	2023-10-26
Location	California, United States Colorado, United States Kansas, United States Ohio, United States Oklahoma, United States Texas, United States Virginia, United States
Prior IO Allowed	Yes
CRC-directed	Yes
Status	Recruiting
Drugs	BET Bromodomain Inhibitor ZEN-3694, encorafenib
Tags	MSI-H/ MMRd, MSS/ MMRp
NCT ID	NCT06105021
Title	Phase I Study of Autologous CD8+ and CD4+ Engineered T Cell Receptor T Cells in Subjects With Advanced or Metastatic Solid Tumor
Phase	Phase 1, Phase 2
Date Added	2023-10-27
Location	California, United States Connecticut, United States New York, United States Oregon, United States Tennessee, United States Texas, United States Washington, United States Wisconsin, United States
Prior IO Allowed	Yes
CRC-directed	Yes
Status	Active, not recruiting
Drugs	AFNT-211
Tags	MSI-H/ MMRd, MSS/ MMRp
NCT ID	NCT03223779
Title	Study of TAS-102 Plus Radiation Therapy for the Treatment of the Liver in Patients With Hepatic Metastases From Colorectal Cancer
Phase	Phase 1, Phase 2
Date Added	2017-07-21
Location	Massachusetts, United States
Prior IO Allowed	Yes
CRC-directed	Yes
Status	Active, not recruiting
Drugs	
Tags	MSI-H/ MMRd, MSS/ MMRp
NCT ID	NCT06120127
Title	Postoperative Chemotherapy With/Without Radiotherapy and Immunotherapy for Colorectal Liver Metastases With High Risk of Locally Recurrence
Phase	Phase 2
Date Added	2023-11-07
Location	China
Prior IO Allowed	Yes
CRC-directed	Yes
Status	Recruiting

Drugs	Chemotherapy, PD-1 antibody
Tags	MSI-H/ MMRd, MSS/ MMRp
NCT ID	NCT06253520
Title	Autologous T-cells Genetically Engineered to Express Receptors Reactive Against KRAS Mutations in Conjunction With a Vaccine Directed Against These Antigens in Participants With Metastatic Cancer
Phase	Phase 1
Date Added	2024-02-12
Location	Maryland, United States
Prior IO Allowed	Yes
CRC-directed	Yes
Status	Recruiting
Drugs	Aldesleukin, Cyclophosphamide, Fludarabine
Tags	MSI-H/ MMRd, MSS/ MMRp
NCT ID	NCT06302062
Title	Phase I Clinical Study of Tumor-associated Lymph Node T Cell Therapy for Advanced Solid Tumors
Phase	Phase 1
Date Added	2024-03-08
Location	China
Prior IO Allowed	Yes
CRC-directed	No
Status	Recruiting
Drugs	Cyclophosphamide, IL-2, Serplulimab Injection, Tumor Associated Lymph node T cell
Tags	MSI-H/ MMRd, MSS/ MMRp